Capecitabine-Carboplatin “Most Favorable” Backbone for Advanced Gastroesophageal Adenocarcinoma CapOx does not offer a progression-free survival advantage over CapCar or F-Nal-IrI in previously untreated, advanced gastroesophageal adenocarcinoma.

CapOx does not offer a PFS advantage over CapCar, nor over nanoliposomal irinotecan, leucovorin and fluorouracil, in previously untreated, metastatic or unresectable #gastroesophagealAdenocarcinoma. Presented at @ascocancer.bsky.social conference #GI26.

https://bit.ly/3LYilhR

#GEA #gicsm

Home-Based Anal Cancer Screening Offers Cost-Effective Alternative, Increases Screening Rate Investigators sought to determine the cost-effectiveness of home- versus clinic-based anal cancer screening for increasing uptake among sexual and gender minorities.

Home-based #analcancer screening appears to be a cost-effective option for increasing screening rates among sexual and gender minority individuals. Published in @jamanetworkopen.com.

https://bit.ly/4sX4Kbj

#cancerScreening #ancsm #gicsm

HERIZON: Zanidatamab Extends PFS in Advanced HER2+ Gastroesophageal Adenocarcinoma - Oncology Nurse Advisor Investigators sought to determine if zanidatamab and chemotherapy, with or without tislelizumab, could extend PFS and OS in patients with untreated locally advanced or metastatic gastroesophageal aden...

Compared to standard care, zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic #gastroesophagealAdenocarcinoma. From @cancertherapyadv.bsky.social.

https://bit.ly/3LVaRME

#gicsm

Compared to standard care, zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma. Presented at #GI26 by Elena Elimova, MD of @pmresearch-uhn.bsky.social.

https://bit.ly/4qniKJU

#GEA #gicsm

As the sun sets in San Francisco and #GI26 comes to a close, we reflect with gratitude on the 3 days we spent with all of you, in person and online. Three full days of learning and connecting, making progress on treatments and care for patients with GI cancers. #gicsm

asco.org/gi-program

Learning about selection criteria & advances in liver-directed therapies & debating role of liver transplantation to improve pt outcomes @ #GI26 Liver-Directed Approaches and Transplantation for Unresectable Colorectal Liver Metastasis session happening now: meetings.asco.org/meetings/202... #gicsm

The 3rd & final intersections session of #GI26 is happening now: “Navigating Early-Onset Gastrointestinal Cancers—From Diagnosis to Survivorship” chaired by Dr. David Shibata and Dr. Wojciech Blogowski. #gicsm

meetings.asco.org/meetings/202...

Exploring novel Tx for GI cancers w BRAF & KRAS mutations during the Intersections Session: Tailoring the Fight—Advances in Targeted Therapies happening now at #GI26; a session that's “very timely,” said co-chair Dr John Gordan. #gicsm meetings.asco.org/meetings/202...
@sandramisale.bsky.social

Standing room only in the breakout session on “Optimizing Management of Liver Tumors in the Setting of Liver Dysfunction: Balancing Tumor Control With Hepatotoxicity” breakout session happening now at #GI26:
meetings.asco.org/meetings/202... #gicsm

“With big data there are a lot of opportunities but also challenges: w/ so much data coming in how do you separate signal from noise?” asked 1st panelist Dr. Caroline Chung @ #GI26 Intersections Session on harnessing #AI for managing GI cancers happening now. #gicsm meetings.asco.org/meetings/202...

Abstracts for #GI26 now available! Discover emerging treatment modalities, the latest clinical trial results, advances in precision medicine, and more—all in the field of gastrointestinal cancers. #gicsm #OncTwitter

View the abstracts: brnw.ch/21wYQVs

10-Week Intervention Program Reduces Fear of Recurrence in Survivors of CRC Researchers assessed the clinical value of an e-health program in reducing fear of cancer recurrence among survivors of colorectal cancer.

TG-iConquerFear, a therapist-guided e-health intervention, appears to significantly and clinically reduce fear of #cancer recurrence in survivors of #colorectalCancer when compared with an augmented control method. Published in @jamanetworkopen.com.

https://bit.ly/4owyd8H

#gicsm

Asynchronous Electronic Consent for Research Acceptable Among Patients With Cancer - Oncology Nurse Advisor Researchers reported on patient acceptance of an e-consent tool for asynchronous delivery of study information and for receiving consent from patients.

The use of an asynchronous e-consent process for prospectively evaluating circulating tumor DNA in patients with colorectal or #pancreaticCancer appeared acceptable among patients in a recent study.

https://bit.ly/4oCHvjC

#pancsm #gicsm

Metastatic CRC Treatment Outcomes Impacted by Sex, Primary Tumor Sidedness In a post hoc analysis of the FIRE-3 trial, researchers evaluated the impact of sex on the efficacy and safety of first-line treatment with FOLFIRI plus cetuximab for patients with RAS/BRAF wild-type mCRC.

Patient sex and primary tumor sidedness impact the efficacy of first-line treatment with cetuximab plus FOLFIRI in patients with RAS wild-type metastatic #colorectalCancer.

https://bit.ly/3Y2TGew

#gicsm

Disparities in CRC Mortality Are Associated With Varied Social Determinants of Health In this study, the researchers aimed to characterize the contributions of Social Vulnerability Index components to colorectal cancer mortality disparities between rural and urban counties.

Disparities in #colorectalCancer mortality between rural and urban areas appear to be associated with certain social determinants of health. Published in @americancancersoc.bsky.social journal Cancer.

https://bit.ly/442qojF

#gicsm #SDOHs

Increased Liver Fat Linked to Poor Outcomes in Colon Cancer Study researchers found no link between more liver fat and poor outcomes in patients with stage I-III rectal cancer.

Having more liver fat is linked to an increased risk of recurrence and worse survival among patients with stage I-III #coloncancer. Published in the journal of the National Cancer Institute.

https://bit.ly/3LMUVvw

#gicsm

Consistent Physical Activity Reduces Risk of Digestive System Cancers, Research Suggests Alongside reducing body mass index, “physical activity may have systematic anticancer effect, such as improving insulin sensitivity, reducing hyperinsulinemia, lowering systemic inflammation, and enhancing immune function,” researchers reported.

Physical activity, particularly at a consistent level in line with guideline recommendations, significantly reduces both risk of and mortality from digestive system #cancers. Published in @jamaoncology.com.

https://bit.ly/3WDdULm

#gicancer #gicsm

Cancer Surgery at High-Quality Hospitals Less Likely for Medicare Advantage Patients A US study investigated whether Medicare Advantage plans limit access to high-quality cancer surgery.

Unlike traditional #Medicare patients, Medicare Advantage enrollees who need major gen/gastro cancer surgery frequently use lower quality hospitals rather than high-quality teaching hospitals. @jamasurgery.com @renalurologynews.bsky.social.

https://bit.ly/4hLzJSA

#gicsm #GCAM

Consistent Physical Activity Reduces Risk of Digestive System Cancers, Research Suggests Alongside reducing body mass index, “physical activity may have systematic anticancer effect, such as improving insulin sensitivity, reducing hyperinsulinemia, lowering systemic inflammation, and enhancing immune function,” researchers reported.

Physical activity, particularly at a consistent level in line with guideline recommendations, significantly reduces both risk of and mortality from digestive system cancers. Published in @jamaoncology.com

https://bit.ly/3WDdULm

#gicsm #gicancer #GastricCancerAwaressMonth ##GCAM

Longer OS Observed in Patients With Stage IV Rectal SCC Than Stage IV Colon SCC Researchers have identified a pattern of longer overall survival in patients with stage IV rectal SCC than among patients with stage IV colon SCC.

Researchers have identified a pattern of longer OS in patients with stage IV rectal small cell carcinoma than among patients with stage IV colon SCC. Presented at #NANETS25.

https://bit.ly/3LeExUi

#gicsm

Long preoperative chemo elicited more pathologic complete responses than short preoperative chemo in PDAC, but no difference in EFS was seen. Presented at #ESMO25 by Dr Michele Reni of San Raffaele Scientific Institute. #gicsm #pancsm #esmo2025

shorturl.at/cPimQ

In patients with unresectable HCC, outcomes with atezolizumab plus bevacizumab are not improved by the addition of low-dose ipilimumab. Presented at #ESMO25 by Dr Philippe Merle of @hospicescivilslyon.bsky.social. #gicsm #hccsm #esmo2025

shorturl.at/MVYsh

Regorafenib plus nivolumab did not improve survival over chemotherapy in patients with previously treated gastric/GEJ cancer, according to results presented at #ESMO25 by Dr David Goldstein of the University of New South Wales. #gicsm #esmo2025

shorturl.at/rDIGV

Researchers Estimate More Than 18 Million Cancer Deaths Worldwide in 2050 Overall, 41.7% of cancer deaths in 2023 were attributed to potentially modifiable risk factors, with behavioral risk factors having the greatest impact.

#Cancerdeaths have increased by more than 70% globally over the last 3 decades and are estimated to continue to climb, with more than 18 million cancer deaths projected in 2050. These findings were published in @thelancetoncol.bsky.social.

https://bit.ly/42Htid9

#lcsm #gicsm #bcsm

Results Support Aspirin Use for Certain Patients With Colorectal Cancer, Researchers Say “Taken together with previous observational, genomic, and early trial data, our findings support the integration of aspirin into clinical practice for a molecularly defined subgroup of patients with c...

Daily aspirin use in the adjuvant setting may reduce the risk of recurrence among patients with colorectal cancer who have somatic alterations in the PI3K pathway, according to research published in @nejm.org. shorturl.at/Y6RqF #gicsm #crcsm

DPYD/UGT1A1 Testing May Decrease Risk of TRAEs in Gastrointestinal Cancer Patients - Oncology Nurse Advisor “Testing decreased the occurrence of severe TRAEs in variant carriers to similar proportions to noncarriers,” the researchers wrote.

DPYD/UGT1A1 testing before treatment with a fluoropyrimidine or irinotecan can reduce the risk of serious TRAEs in patients with #gastrointestinalcancers. Published in @ascopost.bsky.social and @cancertherapyadv.bsky.social.

https://bit.ly/4mUUAo7

#gicsm

NSAIDs May Improve DFS, Delay Recurrence in CRC Adjuvant treatment with NSAIDs can improve disease-free survival and delay recurrence in patients with resected CRC, data suggest.

Adjuvant treatment with NSAIDs can improve disease-free survival and delay recurrence in patients with resected #colorectalcancer, researchers report.

https://bit.ly/4m2IxE3

#gicsm #crcsm

Dr. Eileen O'Reilly is sitting smiling in a white lab coat.

🚨 Happening Soon: @mskcancercenter.bsky.social's Eileen O'Reilly and @mayocliniccancer.bsky.social's Tanios Bekaii-Saab will kick off #ISGIO2025! Join them for opening remarks as program chairs at 9 a.m. CDT/10 a.m. EDT. #GICSM

See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V

NSAIDs May Improve DFS, Delay Recurrence in CRC Adjuvant treatment with NSAIDs can improve disease-free survival and delay recurrence in patients with resected CRC, data suggest.

Adjuvant treatment with NSAIDs can improve disease-free survival and delay recurrence in patients with resected colorectal cancer, researchers report. shorturl.at/5RmfO #gicsm #crcsm #OncSky

Timing of Therapy Linked to Survival, Comorbidities Tied to Treatment Regrets, and More This article highlights recent studies that may help inform the treatment of breast, lung, prostate, and other cancers.

Recent studies have provided new insights that may help inform the treatment of breast, lung, prostate, and other cancers. Read more here: shorturl.at/arVJ2 #blcsm #bcsm #gicsm #gucsm #lcsm #pcsm